Hansoh Pharma’s Promising Cancer Drug Gains EMA Nod

Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.

Hansoh Pharmaceutical’s HS-20093, a B7-H3-targeted antibody-drug conjugate, has gained significant attention as it secures the European Medicines Agency’s Priority Medicines designation, bolstering its development in treating relapsed extensive-stage small-cell lung cancer. This follows its Breakthrough Therapy Designation by the FDA, enhancing its potential market impact. Investors may find interest in the collaboration with GlaxoSmithKline, which holds an exclusive worldwide license for the drug’s development and commercialization.

For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.